Total Payments
$2,316
2024 Payments
$17.91
Companies
14
Transactions
23
Medicare Patients
5,617
Medicare Billing
$726,269
Payment Breakdown by Category
Research$1,561 (67.4%)
Food & Beverage$734.17 (31.7%)
Travel$20.88 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,561 | 2 | 67.4% |
| Food and Beverage | $734.17 | 20 | 31.7% |
| Travel and Lodging | $20.88 | 1 | 0.9% |
Payments by Type
Research
$1,561
2 transactions
General
$755.05
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| INTERCEPT PHARMACEUTICALS, INC. | $1,060 | 1 | $0 (2023) |
| Allergan Inc. | $534.25 | 4 | $0 (2019) |
| ABBVIE INC. | $173.77 | 4 | $0 (2022) |
| Endogastric Solutions, Inc | $124.72 | 3 | $0 (2020) |
| Apollo Endosurgery US Inc | $111.07 | 1 | $0 (2023) |
| Covidien LP | $100.43 | 2 | $0 (2019) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $95.58 | 1 | $0 (2018) |
| Boston Scientific Corporation | $25.05 | 1 | $0 (2020) |
| Medivators Inc. | $23.51 | 1 | $0 (2017) |
| GlaxoSmithKline, LLC. | $17.91 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17.91 | 1 | GlaxoSmithKline, LLC. ($17.91) |
| 2023 | $1,171 | 2 | INTERCEPT PHARMACEUTICALS, INC. ($1,060) |
| 2022 | $21.18 | 1 | ABBVIE INC. ($21.18) |
| 2021 | $152.59 | 3 | AbbVie Inc. ($152.59) |
| 2020 | $44.10 | 2 | Boston Scientific Corporation ($25.05) |
| 2019 | $708.65 | 6 | Allergan Inc. ($502.55) |
| 2018 | $140.69 | 4 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($95.58) |
| 2017 | $59.80 | 4 | Medivators Inc. ($23.51) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2023 | INTERCEPT PHARMACEUTICALS, INC. | OCALIVA (Drug) | — | Cash or cash equivalent | $1,059.75 | Research |
| Study: Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) • Category: Hepatology / Gastroenterology | ||||||
| 02/15/2023 | Apollo Endosurgery US Inc | OverStitch Endoscopic Suturing System (Device) | Food and Beverage | In-kind items and services | $111.07 | General |
| Category: ENDOSCOPIC TISSUE APPROXIMATION DEVICE | ||||||
| 04/08/2022 | ABBVIE INC. | CREON (Drug), VIBERZI, LINZESS | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/29/2021 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $103.92 | General |
| Category: VIROLOGY | ||||||
| 05/21/2021 | AbbVie Inc. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $28.27 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/11/2021 | AbbVie Inc. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/27/2020 | Boston Scientific Corporation | GENERAL - ENDOCHOICE (Device) | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: ENDOCHOICE | ||||||
| 01/07/2020 | Endogastric Solutions, Inc | ESOPHYX (Device) | Food and Beverage | Cash or cash equivalent | $19.05 | General |
| Category: GERD | ||||||
| 12/31/2019 | Allergan Inc. | — | — | Cash or cash equivalent | $500.94 | Research |
| Study: A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis | ||||||
| 12/06/2019 | Covidien LP | EndoFlip (Device) | Food and Beverage | In-kind items and services | $75.43 | General |
| Category: Motility Testing | ||||||
| 11/08/2019 | Endogastric Solutions, Inc | ESOPHYX (Device) | Travel and Lodging | Cash or cash equivalent | $20.88 | General |
| Category: GERD | ||||||
| 11/07/2019 | Endogastric Solutions, Inc | ESOPHYX (Device) | Food and Beverage | Cash or cash equivalent | $84.79 | General |
| Category: GERD | ||||||
| 03/22/2019 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $1.61 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/06/2019 | Covidien LP | Bravo (Device) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Ablation | ||||||
| 10/10/2018 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $95.58 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 03/31/2018 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/15/2018 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/09/2018 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | UCERIS (Drug) | Food and Beverage | In-kind items and services | $13.41 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/20/2017 | Takeda Pharmaceuticals America, Inc. | Amitiza (Drug) | Food and Beverage | In-kind items and services | $10.91 | General |
| Category: Lower GI | ||||||
| 10/02/2017 | Micro-tech Endoscopy USA, Inc. | — | Food and Beverage | Cash or cash equivalent | $14.41 | General |
| Category: GI Endoscopy | ||||||
| 09/26/2017 | Medivators Inc. | DEFENDO STERILE SINGLE USE VALVES (Device) | Food and Beverage | Cash or cash equivalent | $23.51 | General |
| Category: ENDOSCOPY | ||||||
| 05/12/2017 | Shire North American Group Inc | PENTASA (Drug) | Food and Beverage | In-kind items and services | $10.97 | General |
| Category: INTERNAL MEDICINE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | INTERCEPT PHARMACEUTICALS, INC. | $1,060 | 1 |
| A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis | Allergan Inc. | $500.94 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,244 | 1,691 | $544,385 | $157,822 |
| 2022 | 18 | 1,558 | 2,069 | $667,550 | $195,780 |
| 2021 | 17 | 1,516 | 2,081 | $620,360 | $214,875 |
| 2020 | 16 | 1,299 | 1,780 | $543,025 | $157,792 |
Total Patients
5,617
Total Services
7,621
Medicare Billing
$726,269
Procedure Codes
65
All Medicare Procedures & Services
65 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 344 | 597 | $113,590 | $56,318 | 49.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 298 | 449 | $60,615 | $27,925 | 46.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 137 | 137 | $47,950 | $16,492 | 34.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 55 | 56 | $72,800 | $10,570 | 14.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 68 | 73 | $29,200 | $9,999 | 34.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 102 | 107 | $69,550 | $9,015 | 13.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 44 | 67 | $10,050 | $6,345 | 63.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 68 | 68 | $68,000 | $6,071 | 8.9% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 21 | 21 | $19,000 | $3,830 | 20.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 44 | 44 | $11,000 | $3,423 | 31.1% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 25 | 25 | $22,500 | $3,324 | 14.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 11 | 11 | $9,900 | $1,912 | 19.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 24 | $3,030 | $1,511 | 49.9% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $7,200 | $1,087 | 15.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 297 | 484 | $91,420 | $45,451 | 49.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 404 | 668 | $89,680 | $44,487 | 49.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 200 | 200 | $70,000 | $24,892 | 35.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 67 | 68 | $88,400 | $12,697 | 14.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 129 | 130 | $84,500 | $10,767 | 12.7% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 55 | 55 | $10,450 | $9,593 | 91.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 52 | 56 | $22,400 | $8,641 | 38.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 39 | 81 | $12,150 | $6,188 | 50.9% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 33 | 33 | $30,100 | $6,098 | 20.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 72 | 73 | $73,000 | $5,505 | 7.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 76 | 76 | $19,000 | $5,104 | 26.9% |
About Dr. Surinder Saini, M.D
Dr. Surinder Saini, M.D is a Gastroenterology healthcare provider based in Newport Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750304671.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Surinder Saini, M.D has received a total of $2,316 in payments from pharmaceutical and medical device companies, with $17.91 received in 2024. These payments were reported across 23 transactions from 14 companies. The most common payment nature is "" ($1,561).
As a Medicare-enrolled provider, Saini has provided services to 5,617 Medicare beneficiaries, totaling 7,621 services with total Medicare billing of $726,269. Data is available for 4 years (2020–2023), covering 65 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Newport Beach, CA
- Active Since 07/25/2006
- Last Updated 12/23/2011
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1750304671
Products in Payments
- OCALIVA (Drug) $1,060
- ESOPHYX (Device) $124.72
- OverStitch Endoscopic Suturing System (Device) $111.07
- MAVYRET (Drug) $103.92
- LifeVest (Device) $95.58
- EndoFlip (Device) $75.43
- LINZESS (Drug) $61.58
- CREON (Drug) $41.58
- GENERAL - ENDOCHOICE (Device) $25.05
- Bravo (Device) $25.00
- DEFENDO STERILE SINGLE USE VALVES (Device) $23.51
- JEMPERLI (Biological) $17.91
- UCERIS (Drug) $13.41
- PENTASA (Drug) $10.97
- Amitiza (Drug) $10.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Newport Beach
Kenneth J Chang, Md, MD
Gastroenterology — Payments: $1.2M
Gastroenterology $1.2M
Dr. Linda Anh Nguyen, M.d, M.D
Gastroenterology — Payments: $135,118
Gastroenterology $135,118
Mr. Donald Abrahm, M.d, M.D
Gastroenterology — Payments: $102,697
Gastroenterology $102,697
Dr. Christopher Lee, Md, MD
Gastroenterology — Payments: $69,878
Gastroenterology $69,878
Dr. Phuong Nguyen, M.d, M.D
Gastroenterology — Payments: $40,920
Gastroenterology $40,920
Patricia Tsai, M.d, M.D
Gastroenterology — Payments: $28,986
Gastroenterology $28,986